Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug

The Japanese Ministry of Health, Labour and Welfare on Thursday approved BridgeBio Pharma, Inc.‘s (NASDAQ:BBIO) acoramidis, under the brand name Beyonttra, for adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer.

ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy, resulting in heart failure.

AstraZeneca Plc‘s (NASDAQ:AZN) Alexion will be responsible for all commercial activity for Beyonttra in Japan.

Also Read: FDA Approves BridgeBio Pharma’s Drug For Rare ...